ELOX stock enters a 24 patient Phase 2b kidney trial

Published on 10/01/2026 at 01:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ELOX stock enters a 24 patient Phase 2b study after two patients received doses on September 11, 2026. Eloxx reported a USD 4.5 million Q2 net loss.

ELOX, US2901351052, Illustration mit AI erstellt.

ELOX stock enters a 24 patient Phase 2b study after the first two patients received doses in Eloxx Pharmaceuticals' EXACT trial on September 11, 2026. The study tests exaluren in nonsense mutation Alport syndrome, giving the clinical-stage biotechnology company a defined development milestone to track.

Trial sets a 24 patient test

According to Fidelity on September 11, 2026, the randomized, placebo-controlled Phase 2b trial is designed for 24 patients with nonsense mutation Alport syndrome. Its initial placebo-controlled period lasts 16 weeks, with topline data expected in mid-2027 and a final readout expected by the end of 2027.

The program is centered on exaluren, a small-molecule ribosomal modulator intended to promote readthrough of premature stop codons and support production of full-length proteins. The company is also planning a Phase 2 study for autosomal dominant polycystic kidney disease, keeping the pipeline focused on rare kidney disorders.

Coverage adds a USD 32 target

Leerink Partners initiated coverage on September 18, 2026, with a Buy rating and a USD 32.00 price target, according to Futu News. That target puts the analyst view firmly on future clinical execution rather than current commercial revenue.

The financial profile remains development-stage. HDIN Research reported a net loss of USD 4.502 million for Q2 2026, versus USD 1.891 million in Q2 2025, an increase of 138.08 percent. The same June 30, 2026 analysis showed USD 61.96 million in cash and a USD 46.42 million working-capital surplus.

Market value stays highly clinical

Eloxx had a market capitalization of USD 52.6 million as of September 30, 2026, while its 52-week range was USD 8.20 to USD 23.40. Those figures frame a small-cap biotechnology stock whose valuation depends heavily on trial progress, financing capacity and the eventual quality of clinical data.

The next major value test is therefore operational rather than commercial: the 16-week study phase and the mid-2027 topline timetable provide the clearest dated checkpoints for the current pipeline narrative.